ArticleThe American journal on addictions2022
Buprenorphine treatment retention and comorbidities among patients with opioid use disorder in a primary care setting.
Article in The American journal on addictions, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 13 citations in OpenAlex.
- A randomized pilot trial of two forms of behavioral economics intervention to improve engagement in buprenorphine-naloxone treatment among patients with opioid use disorder.Drug and alcohol dependence · 2025Trial
- Daily patterns of opioid and stimulant use and associated risk-behavior outcomes: A cohort study.Addictive behaviors · 2026Article
- The association between the T allele in rs204076 and treatment retention in patients receiving medication for opioid use disorder.Scientific reports · 2026Article
- Subgroup identification of disparities in buprenorphine discontinuation in opioid-use disorder: A Virtual Twins machine learning approach using nationwide United States claims data, 2006-2022.PLOS mental health · 2026Article
- Injectable-Only Overlapping Buprenorphine Starting Protocol in a Low-Threshold Setting.JAMA network open · 2025Observational
- Extended-release Injectable Buprenorphine Initiation in the Emergency Department.The western journal of emergency medicine · 2025Article
- The impact of psychostimulant use on office based buprenorphine treatment retention.Harm reduction journal · 2025Article
- State drug caps associated with fewer Medicaid-covered prescriptions for opioid use disorder, 2017-2022.Health affairs scholar · 2024Article
- Composition of buprenorphine prescribing networks in Medicaid and association with quality of care.Journal of substance use and addiction treatment · 2024Observational
- Buprenorphine treatment retention and comorbidities among patients with opioid use disorder in a primary care setting.The American journal on addictions · 2022Article
- Buprenorphine Receipt and Retention for Opioid Use Disorder Following an Initiative to Increase Access in Primary Care.Journal of addiction medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
BACKGROUND AND
objectivesMore information is needed about comorbidities among patients receiving buprenorphine maintenance treatment and their relationship with retention.
methodsRetrospective electronic health record data over a 5-year period from primary care patients receiving buprenorphine for the treatment of opioid use disorder were examined (N = 899). The present analysis determined the prevalence of comorbidities and examined associations with treatment retention as defined by cumulative duration of buprenorphine prescription.
resultsTobacco use and comorbidities including hypertension were prevalent but did not predict retention according to survival analyses controlling for demographic characteristics. Retention was poorer among patients testing positive for cocaine (HR = 1.38, 95% CI: 1.09-1.74, p = .007) and patients with hepatitis C virus (HR = 1.17, 95% CI: 1.01-1.37, p = .04). CONCLUSION AND SCIENTIFIC SIGNIFICANCE: This study provides new knowledge of previously unexamined associations between comorbidities (e.g., hypertension) and buprenorphine treatment retention. The robust association between cocaine use and poorer buprenorphine retention serves to resolve prior conflicting data in the literature.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.